Uploaded April 2024 | Updated September 2026, 2 weeks ago

---

How a Bispecific Antibody Could Treat NRG1+ Cancers | Merus

NRG1+ cancers are a rare and deadly form of cancer that are caused by a genetic mutation. But there is hope: a new bispecific antibody called MCLA-128 that can block the mutation and activate the immune system to fight the cancer. Watch this video to learn how MCLA-128 works, and how Merus is developing innovative bispecific antibodies for patients with NRG1+ cancers and other diseases.

Check out the complete mechanism of action (MoA) that explains how it works: youtu.be/YUGGTbJZuHY

#science #cancer #oncology

Did you like the video? Please support and LIKE, SUBSCRIBE & COMMENT!

SOURCE
https://merus.nl/technology/multiclonics-platform/

CONNECT WITH US!
Twitter: twitter.com/nymus3d
Facebook: facebook.com/nymus3d
LinkedIn: linkedin.com/company/nymus-3d
Xing: xing.com/pages/nymus3d
Instagram: instagram.com/nymus3d
Behance: behance.net/nymus3d
Artstation: artstation.com/nymus3d

► For more information about us and our capabilities, please visit: nymus3d.com